Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 10

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 10
---
, or otherwise prevent new or modified products from being developed, cleared or approved 
 or commercialized in a timely manner or at all, which could negatively impact our business.                                        |

<div align='center'>6</div>

Risks Related to this Offering and Investment in Our Ordinary Shares

| ● | An active, liquid and orderly                                                                                                     
 trading market for our Ordinary Shares may not develop, which may inhibit the ability of our shareholders to sell Ordinary Shares 
 following this offering.                                                                                                          |

| ● | The market price of our                                                                                                            
 Ordinary Shares may be volatile, which could result in substantial losses for investors purchasing shares in this offering. If our 
 operating and financial performance in any given period does not meet any guidance that we provide to the public, the market price 
 of our Ordinary Shares may decline.                                                                                                |

| ● | Certain recent initial                                                                                                               
 public offerings of companies with public floats comparable to the anticipated public float of Regentis have experienced extreme     
 volatility that was seemingly unrelated to the underlying performance of the respective company.                                     |
| ● | If our operating and financial                                                                                                       
 performance in any given period does not meet any guidance that we provide to the public, the market price of our Ordinary Shares    
 may decline.                                                                                                                         |
| ● | If securities analysts                                                                                                               
 do not publish research or reports about our business or if they publish negative evaluations of our shares, the price of our shares 
 could decline.                                                                                                                       |
| ● | If securities analysts                                                                                                               
 do not publish research or reports about our business or if they publish negative evaluations of our shares, the price of our shares 
 could decline.                                                                                                                       |
| ● | Future sales of our Ordinary                                                                                                         
 Shares could reduce the market price of our Ordinary Shares.                                                                         |
| ● | We have not paid dividends                                                                                                           
 in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value 
 of our shares.                                                                                                                       |
| ● | If we do raise additional                                                                                                            
 capital, shareholders may be subject to dilution.                                                                                    |
| ● | Insiders will continue                                                                                                               
 to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions, 
 including a change of control.                                                                                                       |
| ● | The JOBS Act, allows us                                                                                                              
 to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the   
 amount of